Rhabdomysarcoma of head, neck: clinical, pathological, prognosis analysis of101consecutive cases

doi:10.19438/j.cjoms.2022.02.008

Abstract

Abstract: PURPOSE: To analyze the clinical and pathological features as well as the prognostic factors for head and neck rhabdomyosarcoma(RMS). METHODS: A retrospective study of patients with head and neck RMS treated in Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine from 2006 to 2013 was conducted. The clinical, radiological, pathological, treatment information and follow-up records were collected. Statistical analysis was performed with SPSS 22.0 software package. RESULTS: A total of 101 patients were treated in the given time period, among them 75 were followed-up: 52 were male and 49 were female; 50 were younger than 18 years old, 51 were above 18 years old. Buccal mucosa, parotid region and skull base were the most common sites of the disease. Sixty-five cases were pleomorphic type, 27 were embryonal type and 9 were acinar type. Forty-four patients with IRS gradeⅠ, 39 with grade Ⅱ and 18 with grade Ⅲ. Twenty-nine subjects underwent surgery only, 20 subjects were managed simultaneously with both surgery and chemotherapy, 10 underwent surgery and radiotherapy, 42 were managed by tri-modality. Eight had positive cervical lymph node in final pathological results, no positive surgical margin was found. The 5-year disease free survival(DFS) was 41.3%, while the 5-year overall survival(OS) was 44.0%. CONCLUSIONS: Head and neck rhabdomyosarcoma has a poor 5-year OS and DFS, with IRS grades and tumor sites as the main independent prognostic factors for survival. Radical surgical treatment with negative margins is critical for RMS, and adjuvant therapies such as radiotherapy and chemotherapy may improve local control rate and survival rate of the patients.

Key words: Head and neck, Rhabdomyosarcoma, Treatment, Prognosis

CLC Number:

R739.8

CHEN Yi-ming, Ahemd, JI Tong, REN Zhen-hu. Rhabdomysarcoma of head, neck: clinical, pathological, prognosis analysis of101consecutive cases[J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(2): 146-150.

References

[1] Hettmer S, Li Z, Billin AN, et al.Rhabdomyosarcoma: current challenges and their implications for developing therapies[J]. Cold Spring Harb Perspect Med, 2014, 4(11): a025650.
[2] Hicks J, Flaitz C.Rhabdomyosarcoma of the head and neck in children[J]. Oral Oncol, 2002, 38(5): 450-459.
[3] Sultan I, Qaddoumi I, Yaser S, et al.Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2 600 patients[J]. J Clin Oncol, 2009, 27(20): 3391-3397.
[4] Rodeberg DA, Garcia-Henriquez N, Lyden ER, et al.Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group[J]. J Clin Oncol, 2011, 29(10): 1304-1311.
[5] Meza JL, Anderson J, Pappo AS, et al.Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies Ⅲ and Ⅳ: the Children's Oncology Group[J]. J Clin Oncol, 2006, 24(24): 3844-3851.
[6] Turner JH, Richmon JD.Head and neck rhabdomyosarcoma: a critical analysis of population-based incidence and survival data[J]. Otolaryngol Head Neck Surg, 2011, 145(6): 967-973.
[7] Zevallos JP, Jain K, Roberts D, et al.Modern multimodality therapy for pediatric nonorbital parameningeal sarcomas[J]. Head Neck, 2010, 32(11): 1501-1505.
[8] Bisogno G, De Salvo GL, Bergeron C, et al.Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2019, 20(11): 1566-1575.
[9] Slemmons KK, Yeung C, Baumgart JT, et al.Targeting Hippo-dependent and Hippo-independent YAP1 signaling for the treatment of childhood rhabdomyosarcoma[J]. Cancer Res, 2020, 80(14): 3046-3056.
[10] Vassiliou LV, Lalabekyan B, Jay A, et al.Head and neck sarcomas: a single institute series[J]. Oral Oncol, 2017, 65(1): 16-22.
[11] Li W, Lu H, Wang D.Therapeutic outcome and prognostic factors in sinonasal rhabdomyosarcoma: a single-institution case series[J]. J Cancer Res Clin Oncol, 2019, 145(11): 2793-2802.
[12] Radzikowska J, Kukwa W, Kukwa A, et al.Management of pediatric head and neck rhabdomyosarcoma: a case-series of 36 patients[J]. Oncol Lett, 2016, 12(5): 3555-3562.
[13] Iatrou I, Theologie-Lygidakis N, Schoinohoriti O, et al.Rhabdomyosarcoma of the maxillofacial region in children and adolescents: report of 9 cases and literature review[J]. J Craniomaxillofac Surg, 2017, 45(6): 831-838.
[14] Owosho AA, Brady P, Wolden SL, et al.Long-term effect of chemo-intensity-modulated radiation therapy (chemo-IMRT) on dentofacial development in head and neck rhabdomyosarcoma patients[J]. Pediatr Hematol Oncol, 2016, 33(6): 383-392.
[15] Vasiwala R, Burud I, Lum SK, et al.Embryonal rhabdomyosarcoma of the middle ear presenting with aural polyp and facial nerve palsy[J]. Med J Malaysia, 2015, 70(5): 314-315.
[16] Mazeron R, Oberlin O, Dumas I, et al.Brachytherapy in children with rhabdomyosarcomas of the nasolabial fold[J]. Pediatr Blood Cancer, 2014, 61(7): 1162-1167.
[17] Owosho AA, Huang SC, Chen S, et al.A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-Mutant sclerosing are associated with unfavorable outcome[J]. Oral Oncol, 2016, 61(1): 89-97.
[18] Sanghvi S, Misra P, Patel NR, et al.Incidence trends and long-term survival analysis of sinonasal rhabdomyosarcoma[J]. Am J Otolaryngol, 2013, 34(6): 682-689.
[19] Unsal AA, Chung SY, Unsal AB, et al.A population-based analysis of survival for sinonasal rhabdomyosarcoma[J]. Otolaryngol Head Neck Surg, 2017, 157(1): 142-149.
[20] Siddiqui SH, Siddiqui E, Bavier RD, et al.Clinicopathologic traits and prognostic factors associated with pediatric sinonasal rhabdomyosarcoma[J]. Int Forum Allergy Rhinol, 2019, 9(4): 363-369.
[21] Malempati S, Rodeberg DA, Donaldson SS, et al.Rhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group[J]. Cancer, 2011, 117(15): 3493-3501.
[22] Häuβler SM, Stromberger C, Olze H, et al.Head and neck rhabdomyosarcoma in children: a 20-year retrospective study at a tertiary referral center[J]. J Cancer Res Clin Oncol, 2018, 144(2): 371-379.
[23] Casey DL, Wolden SL.Rhabdomyosarcoma of the head and neck: a multimodal approach[J]. J Neurol Surg B Skull Base, 2018, 79(1): 58-64.
[24] Stepan K, Konuthula N, Khan M, et al.Outcomes in adult sinonasal rhabdomyosarcoma[J]. Otolaryngol Head Neck Surg, 2017, 157(1): 135-141.
[25] Reilly BK, Kim A, Pena MT, et al.Rhabdomyosarcoma of the head and neck in children: review and update[J]. Int J Pediatr Otorhinolaryngol, 2015, 79(9): 1477-1483.
[26] Noujaim J, Thway K, Jones RL, et al.Adult pleomorphic rhabdomyosarcoma: a multicentre retrospective study[J]. Anticancer Res, 2015, 35(11): 6213-6217.
[27] Ognjanovic S, Linabery AM, Charbonneau B, et al.Trends in childhood rhabdomyosarcoma incidence and survival in the united states, 1975-2005[J]. Cancer, 2009, 115(18): 4218-4226.